Targeted Delivery of Small and Macromolecular Drugs
266,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
  • Gebundenes Buch

Site-specific drug delivery and targeting has attracted much research interest from both academia and industry, but because of the wide array of challenges faced in the development of these systems, only a very few targeted therapies have made it to clinics. Bringing together key research, this volume summarizes current progress with a focus on the novel ideas that are being explored to overcome these challenges. This forward-looking volume includes an in-depth review of various aspects of these drug delivery approaches as well as a detailed discussion of a few case studies in each category.

Andere Kunden interessierten sich auch für
Produktbeschreibung
Site-specific drug delivery and targeting has attracted much research interest from both academia and industry, but because of the wide array of challenges faced in the development of these systems, only a very few targeted therapies have made it to clinics. Bringing together key research, this volume summarizes current progress with a focus on the novel ideas that are being explored to overcome these challenges. This forward-looking volume includes an in-depth review of various aspects of these drug delivery approaches as well as a detailed discussion of a few case studies in each category.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Ajit S. Narang works for the Bristol-Myers Squibb, Co. in New Brunswick, New Jersey, in the biopharmaceutical aspects of drug delivery. He has more than eight years of experience in the pharmaceutical industry in the development of oral dosage forms and drug delivery platforms. In addition to the Bristol-Myers Squibb, Co., he has worked for Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) in Gurgaon, India, and Morton Grove Pharmaceuticals (currently a subsidiary of Wockhardt USA LLC, Parsippany, New Jersey) in Vernon Hills, Illinois. He has more than 35 publications and three pending patent applications, and has contributed to the development of several marketed drug products. Ram I. Mahato is a full-time professor in the Department of Pharmaceutical Sciences at the University of Health Science Center, Memphis, Tennessee. He was a research assistant professor at the University of Utah, Salt Lake City; a senior scientist at GeneMedicine, Inc., The Woodland, Texas; and a postdoctoral fellow at the University of Southern California in Los Angeles, Washington University in St. Louis, and Kyoto University, Japan. He is an author or coauthor of 79 peer-reviewed articles and book chapters, and has edited/written three books. He is also a special features editor of Pharmaceutical Research and serves on the editorial boards of the Journal of Drug Targeting, Expert Opinion on Drug Delivery, and Transplantation and Risk Management. His research includes delivery and targeting of small molecules, oligonucleotides, siRNA, and genes.